🇪🇺 ERLOTINIB in European Union

ERLOTINIB (ERLOTINIB) regulatory status in European Union.

Marketing authorisation

EMA

  • Application: EMEA/H/C/005071
  • Marketing authorisation holder: Accord Healthcare S.L.U.
  • Local brand name: Erlotinib Accord
  • Indication: Treatment of lung and pancreatic cancers
  • Status: withdrawn

Read official source →

ERLOTINIB in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is ERLOTINIB approved in European Union?

Yes. EMA has authorised it.

Who is the marketing authorisation holder for ERLOTINIB in European Union?

Accord Healthcare S.L.U. holds the EU marketing authorisation.